Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx is well-positioned for growth with its proprietary communication network for healthcare professionals and a strong potential for revenue growth given its access to the $19 billion pharmaceutical digital advertising market. The company has a solid track record of maintaining profitability through cost actions and strong margins, and is continuously expanding its customer base and partnerships. However, risks include reliance on a concentrated group of customers and partners, as well as potential competition in the market.

Bears say

OptimizeRx is currently facing execution issues with a large client and the effects of continued headwinds related to Most Favored Nation (MFN) pricing and economic uncertainty, leading to a lowered revenue guidance for 2026. Despite growth drivers such as AI-enabled DAAP and mid-tier pharma, the company's revenue visibility remains lower than the previous year and the rest of the year may see a decline in net revenue retention due to large pharma volatility. However, the company's programmatic EHR/DSP connection has the potential to add future growth opportunities in the digital healthcare market.

OptimizeRx Corp (OPRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 7 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.